[go: up one dir, main page]

NO20023097L - Heterocykliske forbindelser med sulfonamidgrupper - Google Patents

Heterocykliske forbindelser med sulfonamidgrupper

Info

Publication number
NO20023097L
NO20023097L NO20023097A NO20023097A NO20023097L NO 20023097 L NO20023097 L NO 20023097L NO 20023097 A NO20023097 A NO 20023097A NO 20023097 A NO20023097 A NO 20023097A NO 20023097 L NO20023097 L NO 20023097L
Authority
NO
Norway
Prior art keywords
ring
atom
nitrogen atom
heterocyclic compounds
hydrogen
Prior art date
Application number
NO20023097A
Other languages
English (en)
Other versions
NO324268B1 (no
NO20023097D0 (no
Inventor
Toru Haneda
Akihiko Tsuruoka
Junichi Kamata
Tadashi Okabe
Keiko Takahashi
Kazumasa Nara
Shinichi Hamaoka
Norihiro Ueda
Toshiaki Wakabayashi
Yasuhiro Funahashi
Taro Semba
Naoko Hata
Yuji Yamamoto
Yoichi Ozawa
Naoko Tsukahara
Takashi Owa
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of NO20023097D0 publication Critical patent/NO20023097D0/no
Publication of NO20023097L publication Critical patent/NO20023097L/no
Publication of NO324268B1 publication Critical patent/NO324268B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
NO20023097A 1999-12-28 2002-06-26 Sulfonamidholdig heterocyklisk forbindelse, farmasoytisk preparat inneholdende den samme, samt anvendelse derav NO324268B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP37548999 1999-12-28
PCT/JP2000/009326 WO2001047891A1 (en) 1999-12-28 2000-12-27 Heterocyclic compounds having sulfonamide groups

Publications (3)

Publication Number Publication Date
NO20023097D0 NO20023097D0 (no) 2002-06-26
NO20023097L true NO20023097L (no) 2002-08-28
NO324268B1 NO324268B1 (no) 2007-09-17

Family

ID=18505601

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20023097A NO324268B1 (no) 1999-12-28 2002-06-26 Sulfonamidholdig heterocyklisk forbindelse, farmasoytisk preparat inneholdende den samme, samt anvendelse derav

Country Status (16)

Country Link
US (1) US6787534B2 (no)
EP (1) EP1243583B1 (no)
JP (1) JP4234344B2 (no)
KR (1) KR100641802B1 (no)
CN (1) CN1217936C (no)
AT (1) ATE305302T1 (no)
AU (1) AU776933B2 (no)
CA (1) CA2395772C (no)
DE (1) DE60022906T2 (no)
ES (1) ES2246922T3 (no)
HU (1) HUP0203973A3 (no)
MX (1) MXPA02006474A (no)
NO (1) NO324268B1 (no)
NZ (1) NZ519380A (no)
RU (1) RU2239631C2 (no)
WO (1) WO2001047891A1 (no)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1481678A4 (en) * 2002-03-05 2009-12-30 Eisai R&D Man Co Ltd ANTITUMORAL AGENT CONTAINING A SULFONAMIDE-CONTAINING HETEROCYCLIC COMPOUND AND AN ANGIOGENESIS INHIBITOR
US7030115B2 (en) 2002-03-21 2006-04-18 Abbott Laboratories N-sulfonylurea apoptosis promoters
MXPA04009141A (es) * 2002-03-21 2004-11-26 Abbott Lab Promotores de apoptosis, de n-sulfonilurea.
EP1731507A1 (en) 2005-04-26 2006-12-13 Institut National des Sciences Appliquees de Rouen (INSA) New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents
WO2007002433A1 (en) 2005-06-22 2007-01-04 Plexxikon, Inc. Pyrrolo [2, 3-b] pyridine derivatives as protein kinase inhibitors
US7470787B2 (en) * 2005-07-11 2008-12-30 Aerie Pharmaceuticals, Inc. Isoquinoline compounds
WO2007008942A2 (en) * 2005-07-11 2007-01-18 Aerie Pharmaceuticals, Inc. Phenylamino-acetic acid [1-(pyridin-4-yl)-methylidene]-hydrazide derivatives and related compounds as modulators of g protein-coupled receptor kinases for the treatment of eye diseases
WO2007044729A2 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
KR20080093123A (ko) * 2006-02-13 2008-10-20 에프. 호프만-라 로슈 아게 당뇨병 치료용 헤테로바이사이클릭 설폰아마이드 유도체
MX2009001036A (es) * 2006-08-04 2009-04-23 Merz Pharma Gmbh & Co Kgaa Pirazolopirimidinas, proceso para su preparacion y su uso como medicina.
JP5235887B2 (ja) 2006-09-20 2013-07-10 アエリー ファーマシューティカルズ インコーポレイテッド Ｒｈｏキナーゼ阻害剤
RU2418003C2 (ru) * 2006-11-10 2011-05-10 КовЭкс Текнолоджиз Айэлэнд Лимитед Антиангиогенные соединения
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
TWI425945B (zh) * 2007-05-28 2014-02-11 Seldar Pharma Inc 四氫異喹啉－１－酮衍生物或其鹽
US8455514B2 (en) * 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
WO2010126626A2 (en) 2009-05-01 2010-11-04 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
UY32668A (es) * 2009-05-26 2010-12-31 Abbott Lab Agentes inductores de la apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes
US8546399B2 (en) * 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
EP2487175A1 (en) 2009-10-06 2012-08-15 Kyowa Hakko Kirin Co., Ltd. Pharmaceutical product containing aromatic heterocyclic compound
EP2632436B1 (en) 2010-10-29 2018-08-29 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
JP6141188B2 (ja) 2010-11-23 2017-06-07 アッヴィ・インコーポレイテッド アポトーシス誘導剤の塩および結晶の形態
NZ708508A (en) 2010-11-23 2016-06-24 Abbvie Bahamas Ltd Methods of treatment using selective bcl-2 inhibitors
CA2826892A1 (en) * 2011-02-24 2012-08-30 Jiangsu Hansoh Pharmaceutical Co., Ltd. Phosphorus containing compounds as protein kinase inhibitors
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
PT3811943T (pt) 2013-03-15 2023-03-15 Aerie Pharmaceuticals Inc Composto para uso no tratamento de distúrbios oculares
CN104447536B (zh) * 2014-10-25 2017-04-12 大连理工大学 一种n‑2‑喹啉基芳基磺酰胺类化合物的制备方法
WO2016087593A1 (en) * 2014-12-05 2016-06-09 Syngenta Participations Ag Novel fungicidal quinolinylamidines
WO2017086941A1 (en) 2015-11-17 2017-05-26 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
US11389441B2 (en) 2016-08-31 2022-07-19 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
CA3057872A1 (en) 2017-03-31 2018-10-04 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
JP7516245B2 (ja) 2017-12-15 2024-07-16 エランコ アニマル ヘルス ゲー・エム・ベー・ハー 抗蠕虫性４－アミノ－キノリン－３－カルボキサミド誘導体を調製する方法
AU2019337703B2 (en) 2018-09-14 2023-02-02 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
WO2020172615A1 (en) * 2019-02-22 2020-08-27 Glaukos Corporation Compounds for the treatment of ocular disease
GB201919214D0 (en) * 2019-12-23 2020-02-05 Ucb Biopharma Sprl Tetrahydrobenzo-quinoline sulfonamide derivatives useful as IGE modulators
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
WO2022006457A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
WO2022182839A1 (en) 2021-02-25 2022-09-01 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
JP2025509672A (ja) 2022-03-17 2025-04-11 インサイト・コーポレイション Ｊａｋ２ ｖ６１７ｆ阻害剤としての三環式尿素化合物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE9688C (de) T. REMUS in Plauen bei Dresden Filter
DD9688A (no) *
GB662798A (en) 1948-05-06 1951-12-12 American Cyanamid Co Improvements in or relating to the production of sulphonamides and intermediates thereof
NL76414C (no) * 1949-07-23
US3157684A (en) 1961-02-13 1964-11-17 Atomic Energy Authority Uk Tritiated-2-methyl-naphthaquinol-(1, 4)-diphosphoric acids
US3801321A (en) * 1972-07-18 1974-04-02 Eastman Kodak Co Photothermographic element,composition and process
GB1492029A (en) 1974-01-30 1977-11-16 Bellon R Lab 4-oxo-1,4-dihydro-1,6-benzo-(h)-naphthyridine-3-carboxylic acid derivatives useful as anti-bacterial agents and their preparation
US4343804A (en) * 1979-03-26 1982-08-10 A. H. Robins Company, Inc. 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds
US4333760A (en) 1980-08-22 1982-06-08 E. I. Du Pont De Nemours And Company Herbicidal sulfonamides
JPS59220733A (ja) 1983-05-30 1984-12-12 Konishiroku Photo Ind Co Ltd ハロゲン化銀写真感光材料
DE3422824A1 (de) 1984-06-20 1986-01-02 Celamerck Gmbh & Co Kg, 6507 Ingelheim Neue herbizid wirksame sulfonylharnstoffe
DE3686688T2 (de) 1985-06-24 1993-03-18 Merck & Co Inc Verwendung von sulfanilamido quinoxalinen zur behandlung von neoplastischen krankheiten.
AU600992B2 (en) 1986-10-28 1990-08-30 Smith Kline & French Laboratories Limited Tetrahydroisoquinolin-2-yl derivatives of carboxylic acids
US5089633A (en) * 1987-04-28 1992-02-18 Georgia Tech Research Corporation Substituted isocoumarins
DE3804990A1 (de) 1988-02-18 1989-08-31 Basf Ag Herbizid wirksame, heterocyclisch substituierte sulfonamide
JPH02149562A (ja) 1988-11-30 1990-06-08 Nisshin Flour Milling Co Ltd 相間移動触媒を用いた１，４−ジヒドロピリジン誘導体の製造方法
ZA903588B (en) 1989-05-16 1991-02-27 Merrell Dow Pharma Excitatory amino acid antagonists
JPH03150560A (ja) 1989-11-08 1991-06-26 Konica Corp ハロゲン化銀カラー写真感光材料
DE4102234A1 (de) 1991-01-23 1992-07-30 Dresden Arzneimittel Neue (alpha)-aminochinolinoyl-(3)-penicilline, verfahren zu deren herstellung und diese enthaltende antibakterielle mittel
JPH06199047A (ja) 1993-01-08 1994-07-19 New Oji Paper Co Ltd 感熱記録体
DK0673937T3 (da) * 1993-09-10 2004-03-22 Eisai Co Ltd Bicyclisk heterocyclisk sulfonamid og sulfonsyreesterderivater
JPH07138493A (ja) 1993-11-19 1995-05-30 Konica Corp 金属錯体化合物及び該化合物を用いた光記録媒体
US5529999A (en) 1994-03-04 1996-06-25 Eli Lilly And Company Antitumor compositions and methods of treatment
FR2725719B1 (fr) * 1994-10-14 1996-12-06 Jouveinal Inst Rech Diazepino-indoles inhibiteurs de phosphodiesterases iv
WO1997015308A1 (en) * 1995-10-23 1997-05-01 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
DE19727117A1 (de) 1997-06-26 1999-01-07 Boehringer Ingelheim Pharma Phenylalkylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
ES2341843T3 (es) * 2000-02-03 2010-06-29 EISAI R&D MANAGEMENT CO., LTD. Inhibidores de la expresion de integrina.

Also Published As

Publication number Publication date
ES2246922T3 (es) 2006-03-01
CN1217936C (zh) 2005-09-07
CN1414952A (zh) 2003-04-30
DE60022906D1 (de) 2006-02-09
RU2002120515A (ru) 2004-01-10
AU2228301A (en) 2001-07-09
NO324268B1 (no) 2007-09-17
CA2395772C (en) 2010-09-28
ATE305302T1 (de) 2005-10-15
AU776933B2 (en) 2004-09-23
EP1243583A4 (en) 2003-08-20
DE60022906T2 (de) 2006-07-06
US6787534B2 (en) 2004-09-07
KR20020068388A (ko) 2002-08-27
NO20023097D0 (no) 2002-06-26
CA2395772A1 (en) 2001-07-05
EP1243583B1 (en) 2005-09-28
EP1243583A1 (en) 2002-09-25
RU2239631C2 (ru) 2004-11-10
WO2001047891A1 (en) 2001-07-05
HUP0203973A3 (en) 2004-07-28
JP4234344B2 (ja) 2009-03-04
US20030144507A1 (en) 2003-07-31
MXPA02006474A (es) 2002-11-29
KR100641802B1 (ko) 2006-11-02
NZ519380A (en) 2004-10-29
HUP0203973A2 (hu) 2003-03-28

Similar Documents

Publication Publication Date Title
NO20023097D0 (no) Heterocykliske forbindelser med sulfonamidgrupper
DK1052254T3 (da) Nitrogen-holdig heterocykliske derivater og medicin deraf
DK1178967T3 (da) Quinolinderivater som inhibitorer af MEK-enzymer
ATE366724T1 (de) Kondensierte heterocyclische derivate
NO20060219L (no) Forbindelser
WO2003024967A3 (en) Indolizines as kinase protein inhibitors
MEP61208A (en) Novel compounds having inhibitory activity against sodium-dependant transporter
DE69903923D1 (de) Bizyklische pyrrolderivate als mcp-1 inhibitoren
BR0315405A (pt) Compostos inibidores da integrase tricìclica pré-organizados
NO20023456D0 (no) Nitrogenholdige forbindelser og farmasöytiske preparater inneholdende de samme
NO20021528D0 (no) Kinuklidinforbindelser og medikamenter inneholdende de samme som den aktive bestanddel
DE60231414D1 (de) 3-substituierte 4-pyrimidonderivate
EP1642880A4 (en) PROTEIN INHIBITORS OF THE HSP90 FAMILY
ATE277011T1 (de) Flouride von 4-substituierten piperidin-derivaten
ATE305930T1 (de) Substituierte benzopyran derivate gegen arrhythmie
DE60217185D1 (de) MIKROBIOZIDE N-PHENYL-N-i4-(4-PYRIDYL)-2-PYRIMIDIN-2-YLö-AMIN-DERIVATE
DE69924887D1 (de) Antibakterielle mittel
ATE449773T1 (de) Homomorpholinoxazolidinone als antibakterielle mittel
EA200001248A1 (ru) Новые линейные и циклические производные мочевины, способ их получения и их содержащие фармацевтические композиции
NO20053302D0 (no) Imidazolderivater med affinitet for alfa 2-reseptoraktivitet.
ATE220063T1 (de) 4-alkylthio-pyrimidin-5-ylessigsäure derivate
GB0427491D0 (en) Process and compounds

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees